Humana Inc vs Zeta Global Holdings Corp — how do they compare? Humana Inc trades at $442.01 (market cap $47.61B), while Zeta Global Holdings Corp trades at $33.37 (market cap $8.47B). The key difference: Humana Inc is far larger — about 5.6× Zeta Global Holdings Corp's market cap, and Humana Inc pays a 0.89% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Zeta Global Holdings Corp for 18 Days on average.
| HUM | ZETA | |
|---|---|---|
Market Cap | $47.61B | $8.47B |
Volume | 1,827,332 | 6,964,745 |
Sector | Health | Technology |
52-Week High | $409.85 | $33.74 |
52-Week Low | $163.67 | $14.55 |
Typical Hold Time | 53 Days | 18 Days |
Enterprise Value | $54.97B | $8.36B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
ZETA trades at $33.74, up 2.4% today and near its 52-week high. The stock shows a bullish technical trend with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, revenue is projected to grow to $1.6 billion in 2026, but the company remains unprofitable with a net margin of -0.14%. Recent news highlights expansion into the U.K. and strong customer growth, with 75% of analysts rating the stock a Buy.
The outlook is cautiously optimistic, driven by AI-led growth and market share gains, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $32.40, slightly below the current price, suggesting limited near-term upside despite bullish sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →